Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Identifieur interne : 003653 ( PubMed/Corpus ); précédent : 003652; suivant : 003654Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Auteurs : Anna Kotsia ; Emmanouil S. Brilakis ; Claes Held ; Christopher Cannon ; Gabriel P. Steg ; Bernhard Meier ; Frank Cools ; Marc J. Claeys ; Jan H. Cornel ; Philip Aylward ; Basil S. Lewis ; Douglas Weaver ; Gunnar Brandrup-Wognsen ; Susanna R. Stevens ; Anders Himmelmann ; Lars Wallentin ; Stefan K. JamesSource :
- American heart journal [ 1097-6744 ] ; 2014.
English descriptors
- KwdEn :
- Acute Coronary Syndrome (drug therapy), Acute Coronary Syndrome (epidemiology), Adenosine (analogs & derivatives), Adenosine (therapeutic use), Aged, Electrocardiography, Female, Follow-Up Studies, Global Health, Humans, Incidence, Male, Middle Aged, Platelet Aggregation Inhibitors (therapeutic use), Purinergic P2Y Receptor Antagonists (therapeutic use), Retrospective Studies, Risk Factors, Survival Rate (trends), Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : Adenosine.
- drug therapy : Acute Coronary Syndrome.
- epidemiology : Acute Coronary Syndrome.
- chemical , therapeutic use : Adenosine, Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists.
- trends : Survival Rate.
- Aged, Electrocardiography, Female, Follow-Up Studies, Global Health, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Risk Factors, Treatment Outcome.
Abstract
Extensive coronary artery disease (CAD) is associated with higher risk. In this substudy of the PLATO trial, we examined the effects of randomized treatment on outcome events and safety in relation to the extent of CAD.
DOI: 10.1016/j.ahj.2014.04.001
PubMed: 24952862
Links to Exploration step
pubmed:24952862Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.</title><author><name sortKey="Kotsia, Anna" sort="Kotsia, Anna" uniqKey="Kotsia A" first="Anna" last="Kotsia">Anna Kotsia</name><affiliation><nlm:affiliation>VA North Texas Healthcare System and UT Southwestern Medical Center, Dallas, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Brilakis, Emmanouil S" sort="Brilakis, Emmanouil S" uniqKey="Brilakis E" first="Emmanouil S" last="Brilakis">Emmanouil S. Brilakis</name><affiliation><nlm:affiliation>VA North Texas Healthcare System and UT Southwestern Medical Center, Dallas, TX. Electronic address: esbrilakis@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Held, Claes" sort="Held, Claes" uniqKey="Held C" first="Claes" last="Held">Claes Held</name><affiliation><nlm:affiliation>Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Cannon, Christopher" sort="Cannon, Christopher" uniqKey="Cannon C" first="Christopher" last="Cannon">Christopher Cannon</name><affiliation><nlm:affiliation>Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Steg, Gabriel P" sort="Steg, Gabriel P" uniqKey="Steg G" first="Gabriel P" last="Steg">Gabriel P. Steg</name><affiliation><nlm:affiliation>INSERM-Unité 698, Paris, France; Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Meier, Bernhard" sort="Meier, Bernhard" uniqKey="Meier B" first="Bernhard" last="Meier">Bernhard Meier</name><affiliation><nlm:affiliation>Bern University Hospital, Bern, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Cools, Frank" sort="Cools, Frank" uniqKey="Cools F" first="Frank" last="Cools">Frank Cools</name><affiliation><nlm:affiliation>AZ KLINA, Brasschaat, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Claeys, Marc J" sort="Claeys, Marc J" uniqKey="Claeys M" first="Marc J" last="Claeys">Marc J. Claeys</name><affiliation><nlm:affiliation>University Hospital Antwerp, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Cornel, Jan H" sort="Cornel, Jan H" uniqKey="Cornel J" first="Jan H" last="Cornel">Jan H. Cornel</name><affiliation><nlm:affiliation>Department of cardiology, Medisch Centrum Alkmaar, Alkmaar, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Aylward, Philip" sort="Aylward, Philip" uniqKey="Aylward P" first="Philip" last="Aylward">Philip Aylward</name><affiliation><nlm:affiliation>South Australian Health and Medical Research Institute, Flinders University and Medical Centre, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Lewis, Basil S" sort="Lewis, Basil S" uniqKey="Lewis B" first="Basil S" last="Lewis">Basil S. Lewis</name><affiliation><nlm:affiliation>Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-ITT, Haifa, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Weaver, Douglas" sort="Weaver, Douglas" uniqKey="Weaver D" first="Douglas" last="Weaver">Douglas Weaver</name><affiliation><nlm:affiliation>Henry Ford Heart and Vascular Institute, Detroit, MI.</nlm:affiliation></affiliation></author><author><name sortKey="Brandrup Wognsen, Gunnar" sort="Brandrup Wognsen, Gunnar" uniqKey="Brandrup Wognsen G" first="Gunnar" last="Brandrup-Wognsen">Gunnar Brandrup-Wognsen</name><affiliation><nlm:affiliation>AstraZeneca Research and Development, Mölndal, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Stevens, Susanna R" sort="Stevens, Susanna R" uniqKey="Stevens S" first="Susanna R" last="Stevens">Susanna R. Stevens</name><affiliation><nlm:affiliation>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.</nlm:affiliation></affiliation></author><author><name sortKey="Himmelmann, Anders" sort="Himmelmann, Anders" uniqKey="Himmelmann A" first="Anders" last="Himmelmann">Anders Himmelmann</name><affiliation><nlm:affiliation>AstraZeneca Research and Development, Mölndal, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Wallentin, Lars" sort="Wallentin, Lars" uniqKey="Wallentin L" first="Lars" last="Wallentin">Lars Wallentin</name><affiliation><nlm:affiliation>Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="James, Stefan K" sort="James, Stefan K" uniqKey="James S" first="Stefan K" last="James">Stefan K. James</name><affiliation><nlm:affiliation>Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24952862</idno><idno type="pmid">24952862</idno><idno type="doi">10.1016/j.ahj.2014.04.001</idno><idno type="wicri:Area/PubMed/Corpus">003653</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003653</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.</title><author><name sortKey="Kotsia, Anna" sort="Kotsia, Anna" uniqKey="Kotsia A" first="Anna" last="Kotsia">Anna Kotsia</name><affiliation><nlm:affiliation>VA North Texas Healthcare System and UT Southwestern Medical Center, Dallas, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Brilakis, Emmanouil S" sort="Brilakis, Emmanouil S" uniqKey="Brilakis E" first="Emmanouil S" last="Brilakis">Emmanouil S. Brilakis</name><affiliation><nlm:affiliation>VA North Texas Healthcare System and UT Southwestern Medical Center, Dallas, TX. Electronic address: esbrilakis@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Held, Claes" sort="Held, Claes" uniqKey="Held C" first="Claes" last="Held">Claes Held</name><affiliation><nlm:affiliation>Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Cannon, Christopher" sort="Cannon, Christopher" uniqKey="Cannon C" first="Christopher" last="Cannon">Christopher Cannon</name><affiliation><nlm:affiliation>Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Steg, Gabriel P" sort="Steg, Gabriel P" uniqKey="Steg G" first="Gabriel P" last="Steg">Gabriel P. Steg</name><affiliation><nlm:affiliation>INSERM-Unité 698, Paris, France; Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Meier, Bernhard" sort="Meier, Bernhard" uniqKey="Meier B" first="Bernhard" last="Meier">Bernhard Meier</name><affiliation><nlm:affiliation>Bern University Hospital, Bern, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Cools, Frank" sort="Cools, Frank" uniqKey="Cools F" first="Frank" last="Cools">Frank Cools</name><affiliation><nlm:affiliation>AZ KLINA, Brasschaat, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Claeys, Marc J" sort="Claeys, Marc J" uniqKey="Claeys M" first="Marc J" last="Claeys">Marc J. Claeys</name><affiliation><nlm:affiliation>University Hospital Antwerp, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Cornel, Jan H" sort="Cornel, Jan H" uniqKey="Cornel J" first="Jan H" last="Cornel">Jan H. Cornel</name><affiliation><nlm:affiliation>Department of cardiology, Medisch Centrum Alkmaar, Alkmaar, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Aylward, Philip" sort="Aylward, Philip" uniqKey="Aylward P" first="Philip" last="Aylward">Philip Aylward</name><affiliation><nlm:affiliation>South Australian Health and Medical Research Institute, Flinders University and Medical Centre, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Lewis, Basil S" sort="Lewis, Basil S" uniqKey="Lewis B" first="Basil S" last="Lewis">Basil S. Lewis</name><affiliation><nlm:affiliation>Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-ITT, Haifa, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Weaver, Douglas" sort="Weaver, Douglas" uniqKey="Weaver D" first="Douglas" last="Weaver">Douglas Weaver</name><affiliation><nlm:affiliation>Henry Ford Heart and Vascular Institute, Detroit, MI.</nlm:affiliation></affiliation></author><author><name sortKey="Brandrup Wognsen, Gunnar" sort="Brandrup Wognsen, Gunnar" uniqKey="Brandrup Wognsen G" first="Gunnar" last="Brandrup-Wognsen">Gunnar Brandrup-Wognsen</name><affiliation><nlm:affiliation>AstraZeneca Research and Development, Mölndal, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Stevens, Susanna R" sort="Stevens, Susanna R" uniqKey="Stevens S" first="Susanna R" last="Stevens">Susanna R. Stevens</name><affiliation><nlm:affiliation>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.</nlm:affiliation></affiliation></author><author><name sortKey="Himmelmann, Anders" sort="Himmelmann, Anders" uniqKey="Himmelmann A" first="Anders" last="Himmelmann">Anders Himmelmann</name><affiliation><nlm:affiliation>AstraZeneca Research and Development, Mölndal, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Wallentin, Lars" sort="Wallentin, Lars" uniqKey="Wallentin L" first="Lars" last="Wallentin">Lars Wallentin</name><affiliation><nlm:affiliation>Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="James, Stefan K" sort="James, Stefan K" uniqKey="James S" first="Stefan K" last="James">Stefan K. James</name><affiliation><nlm:affiliation>Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.</nlm:affiliation></affiliation></author></analytic><series><title level="j">American heart journal</title><idno type="eISSN">1097-6744</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Coronary Syndrome (drug therapy)</term><term>Acute Coronary Syndrome (epidemiology)</term><term>Adenosine (analogs & derivatives)</term><term>Adenosine (therapeutic use)</term><term>Aged</term><term>Electrocardiography</term><term>Female</term><term>Follow-Up Studies</term><term>Global Health</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Platelet Aggregation Inhibitors (therapeutic use)</term><term>Purinergic P2Y Receptor Antagonists (therapeutic use)</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Survival Rate (trends)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Acute Coronary Syndrome</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Acute Coronary Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine</term><term>Platelet Aggregation Inhibitors</term><term>Purinergic P2Y Receptor Antagonists</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Electrocardiography</term><term>Female</term><term>Follow-Up Studies</term><term>Global Health</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Extensive coronary artery disease (CAD) is associated with higher risk. In this substudy of the PLATO trial, we examined the effects of randomized treatment on outcome events and safety in relation to the extent of CAD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24952862</PMID><DateCreated><Year>2014</Year><Month>06</Month><Day>23</Day></DateCreated><DateCompleted><Year>2014</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6744</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>American heart journal</Title><ISOAbbreviation>Am. Heart J.</ISOAbbreviation></Journal><ArticleTitle>Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.</ArticleTitle><Pagination><MedlinePgn>68-75.e2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ahj.2014.04.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-8703(14)00210-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Extensive coronary artery disease (CAD) is associated with higher risk. In this substudy of the PLATO trial, we examined the effects of randomized treatment on outcome events and safety in relation to the extent of CAD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were classified according to presence of extensive CAD (defined as 3-vessel disease, left main disease, or prior coronary artery bypass graft surgery). The trial's primary and secondary end points were compared using Cox proportional hazards regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 15,388 study patients for whom the extent of CAD was known, 4,646 (30%) had extensive CAD. Patients with extensive CAD had more high-risk characteristics and experienced more clinical events during follow-up. They were less likely to undergo percutaneous coronary intervention (58% vs 79%, P < .001) but more likely to undergo coronary artery bypass graft surgery (16% vs 2%, P < .001). Ticagrelor, compared with clopidogrel, reduced the composite of cardiovascular death, myocardial infarction, and stroke in patients with extensive CAD (14.9% vs 17.6%, hazard ratio [HR] 0.85 [0.73-0.98]) similar to its reduction in those without extensive CAD (6.8% vs 8.0%, HR 0.85 [0.74-0.98], Pinteraction = .99). Major bleeding was similar with ticagrelor vs clopidogrel among patients with (25.7% vs 25.5%, HR 1.02 [0.90-1.15]) and without (7.3% vs 6.4%, HR 1.14 [0.98-1.33], Pinteraction = .24) extensive CAD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with extensive CAD have higher rates of recurrent cardiovascular events and bleeding. Ticagrelor reduced ischemic events to a similar extent both in patients with and without extensive CAD, with bleeding rates similar to clopidogrel.</AbstractText><CopyrightInformation>Published by Mosby, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kotsia</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VA North Texas Healthcare System and UT Southwestern Medical Center, Dallas, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brilakis</LastName><ForeName>Emmanouil S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>VA North Texas Healthcare System and UT Southwestern Medical Center, Dallas, TX. Electronic address: esbrilakis@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>Claes</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cannon</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steg</LastName><ForeName>Gabriel P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>INSERM-Unité 698, Paris, France; Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Bern University Hospital, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cools</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>AZ KLINA, Brasschaat, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claeys</LastName><ForeName>Marc J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>University Hospital Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornel</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of cardiology, Medisch Centrum Alkmaar, Alkmaar, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aylward</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>South Australian Health and Medical Research Institute, Flinders University and Medical Centre, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Basil S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-ITT, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Henry Ford Heart and Vascular Institute, Detroit, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandrup-Wognsen</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AstraZeneca Research and Development, Mölndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Susanna R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Himmelmann</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AstraZeneca Research and Development, Mölndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallentin</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Stefan K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00391872</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Heart J</MedlineTA><NlmUniqueID>0370465</NlmUniqueID><ISSNLinking>0002-8703</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058921">Purinergic P2Y Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>GLH0314RVC</RegistryNumber><NameOfSubstance UI="C503700">Ticagrelor</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D054058" MajorTopicYN="N">Acute Coronary Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058921" MajorTopicYN="N">Purinergic P2Y Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>04</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24952862</ArticleId><ArticleId IdType="pii">S0002-8703(14)00210-5</ArticleId><ArticleId IdType="doi">10.1016/j.ahj.2014.04.001</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003653 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003653 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24952862
|texte= Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24952862" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |